PTCT Q3 2022 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$217M+56.5% YoY

Gross Profit

$203M93.5% margin

Operating Income

-$73M-33.8% margin

Net Income

-$109M-50.3% margin

EPS (Diluted)

$-1.53

QoQ Revenue Growth

+31.2%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$64M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$1.8B

Stockholders' Equity

-$227M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$217M	$139M	+56.5%
Gross Profit	$203M	$132M	+53.6%
Operating Income	-$73M	-$93M	+21.0%
Net Income	-$109M	-$134M	+18.2%

Geographic Segments

Non-US

$77M58%

United States

$55M42%